 Shares of Mallinckrodt NYSE:MNK decreased 24 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 25.30 over the past year to 1.89, which beat the estimate of 1.35.Revenue of 700,900,000 decreased by 14.87 year over year, which beat the estimate of 635,330,000.Guidance Earnings guidance hasnt been issued by the company for now.Mallinckrodt hasnt issued any revenue guidance for the time being.Details Of The Call Date: Aug 04, 2020View more earnings on MNKTime: 08:30 AMET Webcast URL: Companys 52-week high was at 6.87Companys 52-week low was at 1.00Price action over last quarter: down 25.17Company Overview Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients.See more from Benzinga 52 Stocks Moving In Wednesdays Regular-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 